FDA Symlin Reviewer Cautions Against Diabetes Claims For Anorexic Agents
Executive Summary
FDA should be wary of approving a diabetes claim for a drug whose mechanism of action is reducing body weight, FDA reviewer Robert Misbin, MD, said in briefing materials prepared for the advisory committee review of Amylin's Symlin.
You may also be interested in...
Amylin Symlin Study Will Evaluate Hypoglycemia Risk During Dose Initiation
Amylin is planning a six-week Symlin safety study to evaluate the increased incidence of hypoglycemia associated with the antidiabetic agent, the company said following a July 26 FDA advisory committee recommendation against approval of the drug.
Roche Agenda For 2001 Includes Kytril NDA For Post-Op Use, Pegasys Launch
Roche plans to file an NDA during 2001 for use of the anti-emetic Kytril in post-operative nausea and vomiting, the company said during a recent analysts meeting in Basel.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011